Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months - Trial NCT00682903
Access comprehensive clinical trial information for NCT00682903 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique Hopitaux De Marseille and is currently Completed. The study focuses on Diabetes Complications. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assistance Publique Hopitaux De Marseille
Timeline & Enrollment
N/A
Jan 01, 2008
Feb 01, 2011
Primary Outcome
The HbA1c, the witness of the quality of the metabolic balance, in 6 and 12 months. We shall compare the deltae of HbA1c between the period of inclusion and 6 and 12 months following the training course in the fonctional insulin therapy
Summary
The objective of the project is to evaluate advantages from the use of a bearable continuous
 interstitial glucose monitoring device (GuardianR) during educative sessions of diabetic
 patients dedicated to functional insulin therapy teaching. This concept of intensified
 treatment is based on testing and explanation of simplified decision making algorithms to
 adapt insulin dose to every true life conditions. As self monitoring of capillary glucose
 level is needed to validate those algorithms, we postulate that using a device able to
 permanently control interstitial glucose readable by both medical team and patient himself
 (during the session and the 5 following days after discharge) could significantly improve
 safety and efficiency of such educative session.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00682903
Device Trial